Patent Foramen Ovale (PFO) Closure Follow-up and Recovery

This information can help you anticipate what to expect the day of and the day after your PFO closure procedure, and what your subsequent follow-up appointments and activity levels will be.

Post-procedural follow-up visit protocol

Prior to discharge

- Physical exam, TTE

1 Month

- Physical exam, TTE

6 Months

- Physical exam, TTE

12 Months

- Physical exam, TTE*

Post-procedural care medical therapy protocol

Day 1+

- One of the following antiplatelet options:

  ASPIRIN® (acetylsalicylic acid) 81-325 mg daily

  Combination:
  ASPIRIN® (acetylsalicylic acid) 50-100 mg daily / Dipyridamole 225-400 mg daily

  Clopidogrel (alone) 75 mg daily

- Antiplatelet therapy should be used indefinitely

You should take appropriate antibiotic therapy consistent with your physician's routine procedures following device implantation.

Post-procedural patient activity level

Day 1

- Hospital rest for up to one day

Day 14+

- Resume to all normal activities

Follow-up and recovery based on the Gore REDUCE Clinical Study.†

* In instances where device stability is in question, fluoroscopic examination without contrast is recommended
† Protocols based on REDUCE Study

TTE: transthoracic echocardiogram
Prophylactic: A medicine or course of action used to prevent disease

It is important to speak with your doctor about the potential benefits and risks of PFO closure.

Learn more at AboutPFO.com and ask your doctor if PFO closure is right for you.

INDICATIONS FOR USE IN THE U.S.: The GORE® CARDIOFORM Septal Occluder is a permanently implanted device indicated for the percutaneous, transcatheter closure of the following defects of the atrial septum: ostium secundum atrial septal defects (ASDs); patent foramen ovale (PFO) to reduce the risk of recurrent ischemic stroke in patients, predominantly between the ages of 18 and 60 years, who have had a cryptogenic stroke due to a presumed paradoxical embolism, as determined by a neurologist and cardiologist following an evaluation to exclude known causes of ischemic stroke. **CONTRAINDICATIONS:** The GORE® CARDIOFORM Septal Occluder is contraindicated for use in patients: unable to take antiplatelet or anticoagulant medications such as aspirin, heparin or warfarin; with anatomy where the GORE® CARDIOFORM Septal Occluder size or position would interfere with other intracardiac or intravascular structures, such as cardiac valves or pulmonary veins; with active endocarditis, or other infections producing bacteremia, or patients with known sepsis within one month of planned implantation, or any other infection that cannot be treated successfully prior to device placement; with known intracardiac thrombi. Refer to *Instructions for Use* at goremedical.com for a complete description of all warnings, precautions and adverse events. $\text{R}_{\text{x Only}}$

This information is intended for education and awareness only. Patients should consult their physician for information on the risks associated with the devices and surgical procedures discussed in this document. All surgical procedures carry potential health risks. Not all patients will be candidates for treatment with these devices, and individual outcomes may vary.

Always follow physician advice on your post-surgery care and recovery.

Caution: U.S. law restricts use of this device on the order of a physician (Rx).

Products listed may not be available in all markets.

W. L. Gore & Associates, Inc.
Flagstaff, AZ 86004
T 800 437 8181 **T** 928 779 2771 goremedical.com

Together, improving life

GORE

AY1011-EN1